MedTrace Logo

Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure

NCT00744341 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2010-09-17

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of IV SLV320 in acute heart failure patients with renal dysfunction.

Conditions

  • Acute Decompensated Heart Failure; Renal Dysfunction

Interventions

DRUG

SLV320

1.25mg i.v. bid

DRUG

SLV320

3.75mg i.v. bid

DRUG

SLV320

7.5mg i.v. bid

DRUG

SLV320

15.0mg i.v. bid

DRUG

Placebo

Sponsors & Collaborators

  • Solvay Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Robyn Bethany · Solvay Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States
  • Canada
  • Chile
  • Denmark
  • France
  • Germany
  • Italy
  • Poland
  • Romania
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00744341 on ClinicalTrials.gov